← Back to Patent Explorer
US5200422A Expired / Lapsed US ⏱️ 0.0 years remaining

Benzimidazole derivatives, their preparation and use

Assignee: NTG Nordic Transport Group AS
•
Filing: 1991-07-17
•
Granted: 1993-04-06
•
Expires: 2011-07-17
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract A compound having the formula ##STR1## wherein R 1 is hydrogen, NH 2 or C 1-6 -alkyl which may be branched; X is O, S, NCN; Y is O, S; R 4 , R 5 , R 6 and R 7 independently of each other are hydrogen, halogen, CF 3 , NO 2 , NH 2 , OH, C 1-6 -alkoxy, C(═O)-phenyl or SO 2 NR I R II wherein R I and R II independently are hydrogen or C 1-6 -alkyl; R 11 is hydrogen, halogen, NO 2 or SO 2 NR'R" wherein R' and R" independently are hydrogen or C 1-6 -alkyl; R 13 is hydrogen, halogen, phenyl, CF 3 , NO 2 ; R 12 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated; R 14 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated; pharmaceutical compositions thereof, and a method of treating a disease in a mammal, including a human, responsive to opening of potassium channels, which comprises administering to a mammal in need thereof an effective amount of a compound as first above indicated, are disclosed.

Inventors

  • 👤 Soren-Peter Olesen
  • 👤 Frank Watjen

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 10:26
CPC Classifications
C; C07; C07D; C07D235/00; C07D235/02; C07D235/04; C07D235/24; C07D235/28; C07D235/26; C07D235/30

Claims Analysis

Total Claims: 9
Claim 1
Independent Claim 163 words
A compound selected from those having the formula ##STR4## wherein R 1 is hydrogen, NH 2 or C 1-6 -alkyl which may be branched; X is O, S, NCN; Y is O, S; R 4 , R 5 , R 6 and R 7 independently of each other are hydrogen, halogen, CF 3 , NO 2 , NH 2 , OH, C 1-6 -alkoxy, C(═O)-phenyl or SO 2 NR I R II wherein R I and R II independently are hydrogen or C 1-6 -alkyl; R 11 is hydrogen, halogen, NO 2 or SO 2 NR'R" wherein R' and R" independently are hydrogen or C 1-6 -alkyl; R 13 is hydrogen, halogen, phenyl, CF 3 , NO 2 ; 1 R is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated; R 14 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated.
Claim 2
Dependent Claim 163 words
A compound selected from those having the formula ##STR4## wherein R 1 is hydrogen, NH 2 or C 1-6 -alkyl which may be branched; X is O, S, NCN; Y is O, S; R 4 , R 5 , R 6 and R 7 independently of each other are hydrogen, halogen, CF 3 , NO 2 , NH 2 , OH, C 1-6 -alkoxy, C(═O)-phenyl or SO 2 NR I R II wherein R I and R II independently are hydrogen or C 1-6 -alkyl; R 11 is hydrogen, halogen, NO 2 or SO 2 NR'R" wherein R' and R" independently are hydrogen or C 1-6 -alkyl; R 13 is hydrogen, halogen, phenyl, CF 3 , NO 2 ; 1 R is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated; R 14 is hydrogen or together with R 13 forms a C 4-7 -carbocyclic ring which may be aromatic or partially saturated.
Claim 3
Dependent Claim 8 words
A compound of claim 1 which is 5-trifluoromethyl-2,3-dihydro-1-(5-chloro-2-hydroxyphenyl)-1H-2-oxo-benzimidazole.
Claim 4
Dependent Claim 8 words
A compound of claim 1 which is 5-trifluoromethyl-2,3-dihydro-1-(5-phenyl-2-hydroxyphenyl)-1H-2-oxo-benzimidazole.
Claim 5
Dependent Claim 8 words
A compound of claim 1 which is 5-trifluoromethyl-6-nitro-2,3-dihydro-1-(3-nitro-5-chloro-2-hydroxyphenyl)-1H-2-oxo-benzimidazole.
Claim 6
Dependent Claim 33 words
A method of treating a disease in a mammal, responsive to opening of potassium channels, which comprises administering to a mammal in need thereof an effective amount of a compound of claim 1.
Claim 7
Dependent Claim 13 words
A method of claim 5 wherein hypertension, asthma, ischemia or convulsions are treated.
Claim 8
Dependent Claim 30 words
A method of claim 5 wherein the compound is administered in the form of a pharmaceutical composition thereof, in which it is present together with a pharmaceutically-acceptable carrier or diluent.
Claim 9
Dependent Claim 18 words
A pharmaceutical composition comprising a therapeutically-effective amount of a compound of claim 1 together with a pharmaceutically-acceptable carrier.

References Cited (Backward Citations)

US3338916A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1996-04-05 1996-10-05 1997-04-06 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2000-04-05 2000-10-05 2001-04-06 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2004-04-05 2004-10-05 2005-04-06 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag